A SPAC III Acquisition Corp. is a blank check company formed solely to merge with a private operating company and take it public. A SPAC III raised $60M in its November 2024 IPO, with proceeds held in trust at approximately $10.00 per share. The SPAC has until November 2026 to close a business combination. A SPAC III generates no operating revenue — it earns only modest interest on its trust account during the search period. Its sponsor, A SPAC III (Holdings) Corp., holds founder shares acquired at nominal cost that convert into equity in the combined company if a deal closes, which is the sponsor's primary economic incentive. A SPAC III's stated acquisition focus is businesses in the ESG and materials technology sector, targeting companies with enterprise values between $100M and $600M. The SPAC has signed a merger agreement with Bioserica International, a BVI holding company with operating subsidiaries in China that develops, manufactures, and sells bio-based antimicrobial materials. The deal values Bioserica at approximately $217.9M, paid entirely in newly issued shares of the post-combination entity. The deal has not yet closed. If it does close, the combined company would have operations entirely in China, exposing investors to PRC regulatory risk, potential VIE structure complications, U.S. delisting risk under the HFCAA, and restrictions on moving cash out of China.